The price control policies that are being discussed in Congress have the potential to harm innovation in the life science industry. But how, exactly?
In this episode, we interview Kirsten Axelsen, Senior Advisor at Charles Rivers Associates , about what would change in biopharma if price controls were implemented.
In this episode, we discuss:
The close relationship between economy and drug development
The U.S.’s role in developing over 40% of the world’s new medicines
The potential reduction of biopharma global revenues by 19%
What it means globally when 8-15 fewer medicines are made per decade
Some flaws in the health technology assessment (HTI) regarding clinical trials
Incubate Policy Lab is the research arm of Incubate Coalition, where we will be releasing reports, whitepapers, and hosting events in partnership with Charles Richards Associates. You can visit our website for more information.
We will be releasing an analysis on the CBO report and how HR 3 will impact life sciences R&D, and another report where we analyze price controls from the venture capital perspective. We also hosted a roundtable, and will be releasing an analysis our findings from experts who attended the event.
As we continue this journey together, we want to hear from you, the listener. Email John@incubatecoalition.org or Ashlyn@incubatecoalition.org what’s top of mind, what story you want to hear, or what you find interesting!
To hear more interviews like this one, subscribe to Making Medicine on Apple Podcasts, Spotify, or your preferred podcast platform.
